<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-124966" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Obeticholic Acid</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Krupa</surname>
            <given-names>Kristina N.</given-names>
          </name>
          <aff>Department of Obstetrics and Gynecology, Medical City Arlington, Arlington, TX USA</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nguyen</surname>
            <given-names>Hiep</given-names>
          </name>
          <aff>Christus Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristina Krupa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hiep Nguyen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-124966.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Obeticholic acid is a medication prescribed for the management of primary biliary cholangitis. This educational activity covers the indications, mechanism of action, contraindications, FDA-issued box warnings, adverse event profile, toxicity, and critical aspects such as dosing, monitoring, and relevant drug interactions associated with obeticholic acid.&#x000a0;Reviewing&#x000a0;pharmacological information regarding obeticholic acid is essential for healthcare professionals&#x000a0;looking to&#x000a0;enhance treatment&#x000a0;for&#x000a0;patients with primary biliary cholangitis.&#x000a0;This knowledge supports informed decision-making while initiating&#x000a0;obeticholic acid regimens and minimizing adverse reactions to ensure targeted, safe, personalized care.</p>
        <p>The session also highlights the importance of the interprofessional healthcare team in managing obeticholic acid therapy effectively. By clarifying roles and promoting collaboration, healthcare professionals&#x000a0;may achieve optimal obeticholic acid administration, improving patient outcomes and care standards.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for obeticholic acid administration.</p></list-item><list-item><p>Evaluate the mechanism of action of obeticholic acid.</p></list-item><list-item><p>Assess the potential adverse drug reactions&#x000a0;associated with&#x000a0;obeticholic acid therapy.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from obeticholic acid therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=124966&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=124966">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-124966.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Obeticholic acid (OCA) is a synthetic derivative of&#x000a0;chenodeoxycholic acid, an endogenous primary bile acid. Obeticholic acid&#x000a0;was initially developed to treat liver and bile duct pathologies and has&#x000a0;demonstrated efficacy&#x000a0;as an anti-cholestatic and antihepatotoxic agent. Obeticholic acid&#x000a0;is United States Food and Drug Administration (FDA)-approved for treating primary biliary cholangitis (PBC). The use of OCA for primary sclerosing cholangitis and nonalcoholic steatohepatitis is still under study.<xref ref-type="bibr" rid="article-124966.r1">[1]</xref>&#x000a0;Obeticholic acid is a novel therapy and the first FDA-approved semi-synthetic agonist of the farnesoid X receptor.<xref ref-type="bibr" rid="article-124966.r2">[2]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>
<bold>Primary biliary cholangitis</bold>
</p>
        <p>Obeticholic acid has only&#x000a0;received FDA approval&#x000a0;to treat PBC, a disease characterized by progressive inflammatory destruction of small intrahepatic bile ducts.<xref ref-type="bibr" rid="article-124966.r3">[3]</xref> Obeticholic acid is approved for use in combination with ursodeoxycholic acid (UDCA) for patients who have had an inadequate biochemical response after a year of UDCA monotherapy. Obeticholic acid is FDA-approved for the treatment of adult patients with PBC without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension, either in combination with UDCA for those with an inadequate response to UDCA or as monotherapy for patients unable to tolerate UDCA. Obeticholic acid received accelerated approval for this indication based on data demonstrating reduced alkaline phosphatase (ALP) levels. A&#x000a0;benefit regarding disease-related symptoms or survival has not been established.<xref ref-type="bibr" rid="article-124966.r4">[4]</xref>&#x000a0;A&#x000a0;retrospective analysis evaluated the role of OCA in managing PBC, particularly as a second-line therapy after UDCA treatment. Approximately 8% of patients were prescribed OCA due to UDCA intolerance. The study highlights OCA's efficacy in reducing alkaline phosphatase levels in PBC, emphasizing its emerging role as a therapeutic option&#x000a0;with greater efficacy than&#x000a0;UDCA.<xref ref-type="bibr" rid="article-124966.r5">[5]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>
<bold>Primary sclerosing cholangitis</bold>
</p>
        <p>Primary sclerosing cholangitis is characterized by progressive inflammation, fibrosis, and sclerosis of medium to large-sized bile ducts leading to biliary strictures. There is no known effective medical therapy. A phase 2 trial studying OCA as a treatment for&#x000a0;PSC in 77 patients over 24 weeks&#x000a0;showed reductions in serum ALP in patients receiving OCA at 5 and 10 mg doses.<xref ref-type="bibr" rid="article-124966.r6">[6]</xref>&#x000a0;</p>
        <p>
<bold>Nonalcoholic steatohepatitis</bold>
</p>
        <p>The FDA does not approve OCA to treat nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH); however, its effects on these&#x000a0;conditions have been documented.&#x000a0;During a multicenter, randomized, controlled phase 3 trial, patients were given a placebo, OCA 10 mg,&#x000a0;or OCA 25 mg daily for 18 months to patients in&#x000a0;3 groups: adults with NASH, NAFLD, or signs of fibrosis stages F2-F3 (or F1 with accompanying comorbidity). An interim&#x000a0;analysis&#x000a0;revealed that OCA 25 mg significantly improved&#x000a0;inflammation and&#x000a0;fibrosis&#x000a0;in patients with NASH.<xref ref-type="bibr" rid="article-124966.r7">[7]</xref> Similarly, another randomized control trial&#x000a0;showed that administration of OCA 40 mg/d for 72 weeks&#x000a0;in patients with NASH improved the histological features and fibrosis associated with this condition.<xref ref-type="bibr" rid="article-124966.r8">[8]</xref></p>
        <p>A systematic review and meta-analysis evaluated the efficacy of OCA for treating NASH. Five randomized controlled trials were analyzed, focusing on biochemical and histological outcomes in&#x000a0;patients with NASH diagnosed by imaging or histology.&#x000a0;Obeticholic acid&#x000a0;administration significantly&#x000a0;reduced liver function marker levels (ie, alanine transaminase and aspartate aminotransferase) and reduced fibrosis and steatosis.<xref ref-type="bibr" rid="article-124966.r9">[9]</xref>&#x000a0;Obeticholic acid has also shown promising results&#x000a0;for&#x000a0;conditions such as NAFLD with&#x000a0;type 2 diabetes and bile acid diarrhea.<xref ref-type="bibr" rid="article-124966.r10">[10]</xref><xref ref-type="bibr" rid="article-124966.r11">[11]</xref></p>
      </sec>
      <sec id="article-124966.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>OCA is a semisynthetic hydrophobic bile acid analog that acts as a highly selective agonist for the farnesoid X-activated receptor (FXR), a nuclear bile acid receptor.<xref ref-type="bibr" rid="article-124966.r2">[2]</xref>&#x000a0;Farnesoid X-activated receptors are primarily expressed in human enterocytes and hepatocytes. Naturally occurring bile acids are the most&#x000a0;common&#x000a0;ligands for FXRs. In enterocytes, FXRs regulate the synthesis of bile acids and release a fibroblast growth factor (FGF-19) into the hepatic portal circulation.<xref ref-type="bibr" rid="article-124966.r12">[12]</xref>&#x000a0;FXRs primarily regulate hepatocyte hepatic triglyceride synthesis, fibrosis, and other metabolic pathways. Once FGF-19 is released into the portal circulation, it binds to the FGFR-4 receptor on the hepatocytes. This receptor complex&#x000a0;eventually suppresses&#x000a0;cholesterol 7&#x003b1;-hydroxylase (CYP7A1), the enzyme responsible for converting cholesterol into bile acids.<xref ref-type="bibr" rid="article-124966.r13">[13]</xref>&#x000a0;</p>
        <p>This primary pathway inhibits bile acid synthesis by the hepatocytes. FXRs in the hepatocytes are also activated by circulating bile acids to stimulate the bile salt export pump (BSEP) to increase bile salt excretion. Upon intake, OCA is metabolized&#x000a0;by the liver into glycine and taurine. Later, these conjugated products are secreted into the bile and absorbed by the small intestine. After&#x000a0;glycine and taurine enter enterohepatic circulation, intestinal microbes deconjugate back into OCA.<xref ref-type="bibr" rid="article-124966.r14">[14]</xref></p>
        <p>Obeticholic acid selectively binds and activates the FXRs of enterocytes and hepatocytes, reducing the toxic levels of bile acids. Compared with naturally occurring bile acids, its binding potency is over 100-fold, effectively blunting the harmful effects of bile acids on hepatic tissues. Reducing this exposure&#x000a0;limits the progression of cholangitic processes such as PBC and PSC.&#x000a0;Obeticholic acid also directly stimulates the BSEP to&#x000a0;reduce circulating bile salts in the liver and biliary tree. While OCA has not been approved for use in patients with NASH,&#x000a0;the data from some studies&#x000a0;suggest OCA's&#x000a0;efficacy&#x000a0;in suppressing hepatic triglyceride synthesis and promoting insulin sensitivity and insulin-dependent activities. This suppression&#x000a0;reduces&#x000a0;the risk of lipid deposition into hepatocytes, reducing the incidence and progression of NASH.<xref ref-type="bibr" rid="article-124966.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Obeticholic acid reaches peak plasma concentrations (Tmax) at about 1.5 hours, and the alkaline phosphatase reduction plateau at about 3 months. Food does not alter absorption.</p>
        <p><bold>Distribution:</bold>&#x000a0;Obeticholic acid and its metabolites&#x000a0;demonstrate plasma protein binding of &#x0003e;99%. The volume of distribution is 618 L.</p>
        <p><bold>Metabolism:</bold> Obeticholic acid is conjugated with glycine or taurine in the liver and secreted into bile. These conjugates are absorbed in the small intestine, leading to enterohepatic recirculation. Deconjugation by intestinal microbiota in the ileum and colon converts them back to OCA, which is reabsorbed or excreted in feces, the principal route of elimination.<xref ref-type="bibr" rid="article-124966.r15">[15]</xref></p>
        <p><bold>Elimination:</bold> Approximately 87% of the dose is excreted in feces via biliary secretion. Less than 3% is excreted in urine.</p>
      </sec>
      <sec id="article-124966.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>OCA is available as a 5 or 10-mg oral tablet for patients with PBC with inadequate response or intolerance to UDCA.&#x000a0;Inadequate response is defined as an ALP level greater than 1.67 times the upper limit of normal or elevated bilirubin greater than&#x000a0;twice the ULN after&#x000a0;1 year of UDCA therapy.<xref ref-type="bibr" rid="article-124966.r16">[16]</xref></p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>The recommended&#x000a0;initial dose is 5 mg once daily, which can be increased to 10 mg daily if the patient does not have a reduction in ALP and bilirubin within&#x000a0;3 months and tolerates the drug well.<xref ref-type="bibr" rid="article-124966.r1">[1]</xref><xref ref-type="bibr" rid="article-124966.r17">[17]</xref>&#x000a0;The effect of&#x000a0;varying&#x000a0;FDA-approved OCA doses is&#x000a0;currently&#x000a0;being studied. One double-blind study&#x000a0;of patients with PBC&#x000a0;with an inadequate response to UDCA demonstrated that OCA doses ranging from 10 to 50 mg daily for&#x000a0;3 months&#x000a0;significantly reduced&#x000a0;ALP, &#x003b3;-glutamyl transpeptidase, and alanine aminotransferase levels.<xref ref-type="bibr" rid="article-124966.r18">[18]</xref> Similarly, another study demonstrated significant improvement in ALP&#x000a0;and other biochemical marker levels&#x000a0;with&#x000a0;OCA 10-50 mg monotherapy.<xref ref-type="bibr" rid="article-124966.r19">[19]</xref>&#x000a0;Pruritus as an adverse effect increased in a dose-dependent manner, and the 10 mg dosage&#x000a0;demonstrated superior tolerability and fewer discontinuations.<xref ref-type="bibr" rid="article-124966.r19">[19]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Obeticholic acid is contraindicated&#x000a0;for patients with decompensated cirrhosis (eg, Child-Pugh class B or C), with a prior history of decompensation events, or&#x000a0;with compensated cirrhosis&#x000a0;and portal hypertension.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>According to product labeling,&#x000a0;any increase in the area under the curve (AUC)&#x000a0;of total OCA in subjects with renal impairment is not clinically significant. Additionally, animal models have demonstrated the beneficial effects of OCA in the kidney by reducing TNF-&#x003b1;-mediated expression of matrix metalloproteinases (MMPs) after liver ischemia-reperfusion.<xref ref-type="bibr" rid="article-124966.r20">[20]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>According to the American Association for the Study of Liver Diseases (AASLD), OCA is not associated with teratogenicity or postnatal abnormalities in animal studies; however, human data are lacking. Due to the insufficient safety data,&#x000a0;administration of OCA during pregnancy is not recommended.</p>
        <p><bold>Breastfeeding considerations: </bold>Per the AASLD, OCA's presence in breast milk has not been determined. Due to insufficient safety data, OCA is&#x000a0;not recommended for patients who are breastfeeding.<xref ref-type="bibr" rid="article-124966.r21">[21]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Obeticholic acid has not been established as safe and effective for pediatric patients.</p>
        <p><bold>Older patients: </bold>No age-related differences in the safety or effectiveness of OCA have been observed.</p>
      </sec>
      <sec id="article-124966.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effects associated with OCA administration include pruritus, fatigue, and abdominal pain and discomfort. Other reported adverse effects include rash, oropharyngeal pain, dizziness, constipation, arthralgia, dyslipidemia, headache, eczema, depression, hypersensitivity reactions, and abnormal thyroid function.<xref ref-type="bibr" rid="article-124966.r1">[1]</xref><xref ref-type="bibr" rid="article-124966.r17">[17]</xref> The incidence of pruritus has been shown to increase in a dose-dependent manner and is&#x000a0;increased when OCA is used as monotherapy. However, if a patient undergoes OCA therapy for&#x000a0;3 months without pruritus, this adverse effect is unlikely to occur subsequently.<xref ref-type="bibr" rid="article-124966.r22">[22]</xref><xref ref-type="bibr" rid="article-124966.r23">[23]</xref><xref ref-type="bibr" rid="article-124966.r24">[24]</xref>&#x000a0;</p>
        <p>If pruritus does occur, it can be managed with bile acid sequestrants, antihistamines, dose reduction, or a temporary dosing interruption.<xref ref-type="bibr" rid="article-124966.r22">[22]</xref> Esophageal varices and ascites were also shown to occur during a 3-year interim analysis of patients in the POISE trial.<xref ref-type="bibr" rid="article-124966.r25">[25]</xref>&#x000a0;Obeticholic acid&#x000a0;is also associated with decreases in high-density lipoprotein cholesterol and triglycerides and increases in low-density lipoprotein (LDL) cholesterol.<xref ref-type="bibr" rid="article-124966.r16">[16]</xref><xref ref-type="bibr" rid="article-124966.r26">[26]</xref><xref ref-type="bibr" rid="article-124966.r27">[27]</xref><xref ref-type="bibr" rid="article-124966.r28">[28]</xref>&#x000a0;However, a double-blind, placebo-controlled study&#x000a0;of patients with NASH showed that atorvastatin could be&#x000a0;in combination with OCA to mitigate LDL changes.<xref ref-type="bibr" rid="article-124966.r29">[29]</xref>&#x000a0;In patients with decompensated cirrhosis or Child-Pugh B or C hepatic impairment who receive more frequent dosing than the recommended starting dosage of 5 mg once weekly, hepatic decompensation and failure have been reported. Patients at risk for hepatic decompensation should be closely monitored while on OCA.</p>
        <p>Dose-dependent liver-related adverse reactions such as jaundice, worsening ascites, portal hypertension, and primary biliary cholangitis flare were also reported in patients with doses of 10 to 50 mg (5 times the recommended dose.) A pooled analysis of 3 placebo-controlled trials&#x000a0;involving patients with PBC revealed that liver-related adverse effects&#x000a0;occurred at a rate of 5.2 per 100 patient exposure years (PEY)&#x000a0;for the 10 mg dose versus 2.4 for the placebo group. Liver-related adverse effects were 19.8 per 100 PEY&#x000a0;for the 25 mg group and 54.5 per 100 PEY for the 50 mg group.<xref ref-type="bibr" rid="article-124966.r1">[1]</xref> Monitoring the patient's liver function&#x000a0;during OCA therapy and liver-related adverse reactions is vital. Patients who experience paradoxical&#x000a0;worsening&#x000a0;of liver disease,&#x000a0;progressive&#x000a0;elevation of liver enzymes, or evidence of hepatic decompensation should discontinue OCA.<xref ref-type="bibr" rid="article-124966.r1">[1]</xref> Patients with cirrhosis presenting with portal hypertension should also discontinue OCA.<xref ref-type="bibr" rid="article-124966.r30">[30]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>Bile acid binding resins (</bold>eg, cholestyramine, colestipol, colesevelam): Obeticholic acid absorption and effectiveness may be reduced if administered concurrently with bile acid binding resins. To minimize interaction, OCA should be taken at least 4 hours before or after these resins.</p>
        <p><bold>Warfarin:</bold> Coadministration of OCA with warfarin can lower the international normalized ratio (INR). Monitoring INR levels and adjusting warfarin dosage may be necessary to maintain therapeutic efficacy.</p>
        <p><bold>Inhibitors of bile salt efflux pump:&#x000a0;</bold>Concomitant&#x000a0;administration of OCA with <bold>bile salt efflux pump inhibitors (eg, cyclosporine)&#x000a0;</bold>may lead to bile salt accumulation in the liver, potentially causing clinical symptoms. These combinations&#x000a0;should be&#x000a0;avoided. However, if BSEP inhibitors are necessary, serum transaminase and bilirubin levels should be monitored.&#x000a0;&#x000a0;</p>
        <p><bold>CYP1A2 substrate:</bold> Obeticholic acid can potentially increase the exposure of CYP1A2 substrates.&#x000a0;Serum drug concentrations should be observed in CYP1A2 substrates with narrow therapeutic indexes, such as theophylline and tizanidine.<xref ref-type="bibr" rid="article-124966.r17">[17]</xref><xref ref-type="bibr" rid="article-124966.r24">[24]</xref></p>
      </sec>
      <sec id="article-124966.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>OCA is contraindicated&#x000a0;for patients with complete biliary obstruction.&#x000a0;Obeticholic acid is also contraindicated&#x000a0;for patients with decompensated cirrhosis (eg, Child-Pugh class B or C)&#x000a0;or compensated cirrhosis with evidence of portal hypertension, such as gastroesophageal varices, ascites, or ongoing thrombocytopenia.</p>
        <p>
<bold>Box Warnings</bold>
</p>
        <p><bold>Hepatic decompensation and hepatic failure in primary biliary cholangitis with cirrhosis:&#x000a0;</bold>The FDA has issued a boxed warning stating that administration of OCA to patients with PBC and compensated&#x000a0;or decompensated cirrhosis&#x000a0;is&#x000a0;associated with hepatic decompensation and hepatic failure. These adverse effects&#x000a0;may be fatal or require liver transplantation. The FDA further notes that OCA is contraindicated&#x000a0;for&#x000a0;patients with PBC&#x000a0;and decompensated cirrhosis, a history of decompensation events, or compensated cirrhosis with evidence of portal hypertension. Furthermore,&#x000a0;OBC was found to fatally exacerbate hepatic decompensation and failure in patients with PBC&#x000a0;and decompensated cirrhosis&#x000a0;when administered at&#x000a0;doses higher than normal. Discontinuation of OCA is advised&#x000a0;for patients&#x000a0;with clinical or laboratory indications of hepatic decompensation, compensated cirrhosis with portal hypertension, or clinically significant hepatic adverse reactions.<xref ref-type="bibr" rid="article-124966.r31">[31]</xref><xref ref-type="bibr" rid="article-124966.r32">[32]</xref>&#x000a0;</p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p><bold>Severe pruritus:</bold> Obeticholic acid treatment is associated with severe itching (pruritus) that can interfere with daily activities and may require medical intervention. Management strategies include bile acid binding resins, antihistamines, dose adjustments, or temporary cessation of OCA.<xref ref-type="bibr" rid="article-124966.r9">[9]</xref></p>
        <p><bold>Reduction in high-density lipoprotein-C:</bold> Obeticholic acid treatment is associated with reduced high-density lipoprotein (HDL)-C levels. These reductions were observed across treatment arms compared to placebo. Monitoring lipid levels is recommended during therapy, particularly for patients experiencing significant and sustained decreases in HDL-C.<xref ref-type="bibr" rid="article-124966.r33">[33]</xref></p>
      </sec>
      <sec id="article-124966.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The patient's response and tolerability to OBC and progression of PBC disease should be monitored. Also, any relevant Child-Pugh classifications should be updated regularly, as dosage adjustments&#x000a0;are based on classification changes. Monitoring liver function, including serum bilirubin,&#x000a0;alanine transaminase, aspartate transaminase, and alkaline phosphatase, can be&#x000a0;performed to assess safety and efficacy.<xref ref-type="bibr" rid="article-124966.r1">[1]</xref>&#x000a0;If the patient has a biliary obstruction, evidence of worsening hepatic function indicating risk of decompensation, or liver-related adverse reactions (such as jaundice, worsening ascites, or PBC flare), OCA should be discontinued. OCA is associated with reduced HDL and increased LDL levels. Serum lipid levels should be monitored during treatment. The INR should be monitored for necessary dosage adjustments as OCA is associated with&#x000a0;reduced INR&#x000a0;in patients&#x000a0;receiving warfarin.<xref ref-type="bibr" rid="article-124966.r17">[17]</xref></p>
      </sec>
      <sec id="article-124966.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>For patients with&#x000a0;primary biliary cholangitis, the administration of OCA at doses higher than the recommended maximum (ie, 25 mg or 50 mg once daily)&#x000a0;results&#x000a0;in dose-dependent hepatotoxicity, evidenced by elevations in ascites, portal hypertension, jaundice, and exacerbation of primary biliary cholangitis.&#x000a0;</p>
        <p>
<bold>Management of overdose</bold>
</p>
        <p>There is no antidote for OCA. The FDA recommends closely monitoring the patient and providing appropriate care&#x000a0;during&#x000a0;an overdose.</p>
        <p>
<bold>Recommendations</bold>
</p>
        <p>OCA should be administered only&#x000a0;to patients who&#x000a0;have an inadequate response&#x000a0;or are intolerant to&#x000a0;ursodeoxycholic acid alone.<xref ref-type="bibr" rid="article-124966.r5">[5]</xref></p>
      </sec>
      <sec id="article-124966.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>OCA is a relatively new pharmacologic agent used&#x000a0;for&#x000a0;patients with&#x000a0;conditions&#x000a0;that have few available treatments. Educating clinicians, administrators, patients, and&#x000a0;other healthcare professionals regarding its use and indications is critical. The lack of long-term trials and data also&#x000a0;highlights the need for continuing medical education&#x000a0;of professionals and patients alike, as new data regarding long-term treatment outcomes and adverse events may arise. Therefore, proper physician practice with differing dosages, patient monitoring, and treatment discontinuation is necessary. Patient comorbidities such as simultaneous renal failure, progressive liver fibrosis leading to&#x000a0;cirrhosis, and biliary ductal obstruction must be monitored.</p>
        <p>Current FDA guidelines approve OCA for treating PBC in patients who have failed first-line treatment or cannot tolerateursodeoxycholic acid. The FDA recommends routinely monitoring patients on OCA for PBC disease progression with laboratory and clinical assessments to determine whether dosage adjustment is needed. Close monitoring is also recommended for patients at increased risk of hepatic decompensation, including&#x000a0;patients with worsening liver function and coagulation.&#x000a0;Providers must use their discretion&#x000a0;when prescribing OCA and closely monitor and share outcomes with their patients to make an informed team decision regarding dose adjustments and continuing the medication if adverse events occur and after they resolve.</p>
        <p>Clinical trials&#x000a0;studying the efficacy of OCA&#x000a0;for patients with PBC, PSC, NAFLD, NASH, and type 2 diabetes have all shown promising results. The results of these studies&#x000a0;suggest that OCA, as a monotherapy or in conjunction with conventional therapy, may effectively treat these diseases. More studies are required on the efficacy of OCA against various other hepatic and pancreatic-related&#x000a0;conditions.&#x000a0;The&#x000a0;PeriOperative ISchemic Evaluation, POISE, trial results showed that OCA treatment significantly improved transplant-free survival in patients with PBC compared to the control group.<xref ref-type="bibr" rid="article-124966.r34">[34]</xref>&#x000a0;The primary care physician should&#x000a0;coordinate with the gastroenterologist and hepatologist for optimal use of OCA. The pharmacist should verify dosing, check for potential interactions, and report any discrepancies to the prescriber. An interprofessional team approach and communication among clinicians, hepatologists, pharmacists, and nurses are crucial to&#x000a0;reducing&#x000a0;adverse effects and enhancing patient outcomes&#x000a0;associated with OCA.</p>
      </sec>
      <sec id="article-124966.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=124966&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=124966">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/124966/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=124966">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-124966.s11">
        <title>References</title>
        <ref id="article-124966.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <chapter-title>Obeticholic Acid</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>12</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31644113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Manns</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hirschfield</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>New Treatment Paradigms in Primary Biliary Cholangitis.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>8</issue>
            <fpage>2076</fpage>
            <page-range>2076-2087</page-range>
            <pub-id pub-id-type="pmid">36809835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsuneyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baba</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Morimoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsunematsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Primary Biliary Cholangitis: Its Pathological Characteristics and Immunopathological Mechanisms.</article-title>
            <source>J Med Invest</source>
            <year>2017</year>
            <volume>64</volume>
            <issue>1.2</issue>
            <fpage>7</fpage>
            <page-range>7-13</page-range>
            <pub-id pub-id-type="pmid">28373632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Vincentis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Amato</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cristoferi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gerussi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malinverno</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lleo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colapietro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fiorini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Coco</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brunetto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Niro</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Cotugno</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saitta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cozzolongo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Losito</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giannini</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Labanca</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marzioni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marconi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morgando</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pellicano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vanni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cazzagon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Floreani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chessa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Morelli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Muratori</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pellicelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pompili</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ponziani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tortora</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosina</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Russello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cannav&#x000f2;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Storato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vigan&#x000f2;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abenavoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>D'Ant&#x000f2;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Gasperi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Distefano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scifo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zolfino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Calvaruso</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cuccorese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Palitti</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bertino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Frazzetto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alvaro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mulinacci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Palermo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scaravaglio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Terracciani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Galati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ronca</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zuin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Claar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Izzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Picardi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Invernizzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vespasiani-Gentilucci</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Carbone</surname>
                <given-names>M</given-names>
              </name>
              <collab>on&#x000a0;behalf&#x000a0;of&#x000a0;the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group and, the Italian PBC Registry</collab>
            </person-group>
            <article-title>Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.</article-title>
            <source>Liver Int</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>42</volume>
            <issue>11</issue>
            <fpage>2453</fpage>
            <page-range>2453-2465</page-range>
            <pub-id pub-id-type="pmid">35932095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacDonald</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fenkel</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sass</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Halegoua-DeMarzio</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for primary biliary cholangitis: an assessment of medication candidacy and rates of treatment.</article-title>
            <source>BMC Gastroenterol</source>
            <year>2024</year>
            <month>Jan</month>
            <day>04</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">38178006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kowdley</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Vuppalanchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Floreani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andreone</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>LaRusso</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Trotter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rushbrook</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirschfield</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Schiano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pencek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>MacConell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bowlus</surname>
                <given-names>CL</given-names>
              </name>
              <collab>AESOP Study Investigators</collab>
            </person-group>
            <article-title>A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.</article-title>
            <source>J Hepatol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>94</fpage>
            <page-range>94-101</page-range>
            <pub-id pub-id-type="pmid">32165251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Younossi</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Ratziu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Loomba</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rinella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anstee</surname>
                <given-names>QM</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bedossa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Geier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beckebaum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Newsome</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Sheridan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Trotter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knapple</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lawitz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abdelmalek</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Kowdley</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Montano-Loza</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Boursier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mathurin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bugianesi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mazzella</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Olveira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cortez-Pinto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Graupera</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Orr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gluud</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Dufour</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Campagna</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zaru</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>MacConell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shringarpure</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sanyal</surname>
                <given-names>AJ</given-names>
              </name>
              <collab>REGENERATE Study Investigators</collab>
            </person-group>
            <article-title>Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Dec</month>
            <day>14</day>
            <volume>394</volume>
            <issue>10215</issue>
            <fpage>2184</fpage>
            <page-range>2184-2196</page-range>
            <pub-id pub-id-type="pmid">31813633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neuschwander-Tetri</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Loomba</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sanyal</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lavine</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Van Natta</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Abdelmalek</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Chalasani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dasarathy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hameed</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kowdley</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>McCullough</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terrault</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Tonascia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brunt</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kleiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Doo</surname>
                <given-names>E</given-names>
              </name>
              <collab>NASH Clinical Research Network</collab>
            </person-group>
            <article-title>Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.</article-title>
            <source>Lancet</source>
            <year>2015</year>
            <month>Mar</month>
            <day>14</day>
            <volume>385</volume>
            <issue>9972</issue>
            <fpage>956</fpage>
            <page-range>956-65</page-range>
            <pub-id pub-id-type="pmid">25468160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2024</year>
            <month>Feb</month>
            <day>16</day>
            <volume>103</volume>
            <issue>7</issue>
            <fpage>e37271</fpage>
            <pub-id pub-id-type="pmid">38363900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walters</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Vassie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pruzanski</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-64</page-range>
            <pub-id pub-id-type="pmid">25329562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mudaliar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Sanyal</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marschall</surname>
                <given-names>HU</given-names>
              </name>
              <name>
                <surname>Kipnes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adorini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sciacca</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Clopton</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Castelloe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dillon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pruzanski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.</article-title>
            <source>Gastroenterology</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>145</volume>
            <issue>3</issue>
            <fpage>574</fpage>
            <page-range>574-82.e1</page-range>
            <pub-id pub-id-type="pmid">23727264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mousa</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Lleo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Invernizzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bowlus</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Gershwin</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Advances in pharmacotherapy for primary biliary cirrhosis.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>633</fpage>
            <page-range>633-43</page-range>
            <pub-id pub-id-type="pmid">25543678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitro</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Godio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Fabiani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Scotti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Galmozzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilardi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Caruso</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vigil Chacon</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Crestani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Insights in the regulation of cholesterol 7alpha-hydroxylase gene reveal a target for modulating bile acid synthesis.</article-title>
            <source>Hepatology</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>885</fpage>
            <page-range>885-97</page-range>
            <pub-id pub-id-type="pmid">17654698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Farnesoid X receptor agonists for primary biliary cirrhosis.</article-title>
            <source>Curr Opin Gastroenterol</source>
            <year>2011</year>
            <month>May</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>285</fpage>
            <page-range>285-8</page-range>
            <pub-id pub-id-type="pmid">21297469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Bioequivalence and Pharmacokinetic Profiles of Generic and Branded Obeticholic Acid in Healthy Chinese Subjects Under Fasting and Fed Conditions.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2021</year>
            <volume>15</volume>
            <fpage>185</fpage>
            <page-range>185-193</page-range>
            <pub-id pub-id-type="pmid">33469270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapman</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Obeticholic acid-a new therapy in PBC and NASH.</article-title>
            <source>Br Med Bull</source>
            <year>2020</year>
            <month>May</month>
            <day>15</day>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>95</fpage>
            <page-range>95-104</page-range>
            <pub-id pub-id-type="pmid">32282030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Keam</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Obeticholic Acid: First Global Approval.</article-title>
            <source>Drugs</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>76</volume>
            <issue>12</issue>
            <fpage>1221</fpage>
            <page-range>1221-6</page-range>
            <pub-id pub-id-type="pmid">27406083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirschfield</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Luketic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lindor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kowdley</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bodhenheimer</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Par&#x000e9;s</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trauner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marschall</surname>
                <given-names>HU</given-names>
              </name>
              <name>
                <surname>Adorini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sciacca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beecher-Jones</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Castelloe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.</article-title>
            <source>Gastroenterology</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>148</volume>
            <issue>4</issue>
            <fpage>751</fpage>
            <page-range>751-61.e8</page-range>
            <pub-id pub-id-type="pmid">25500425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kowdley</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Luketic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hirschfield</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Poupon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schramm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rust</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Par&#x000e9;s</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marschall</surname>
                <given-names>HU</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adorini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sciacca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beecher-Jones</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pencek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>D</given-names>
              </name>
              <collab>Obeticholic Acid PBC Monotherapy Study Group</collab>
            </person-group>
            <article-title>A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.</article-title>
            <source>Hepatology</source>
            <year>2018</year>
            <month>May</month>
            <volume>67</volume>
            <issue>5</issue>
            <fpage>1890</fpage>
            <page-range>1890-1902</page-range>
            <pub-id pub-id-type="pmid">29023915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palladini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cagna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Pasqua</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Adorini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Croce</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Perlini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferrigno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berardo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vairetti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2022</year>
            <month>Apr</month>
            <day>24</day>
            <volume>15</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">35631351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarkar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Fleckenstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forde</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Khungar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Molleston</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Afshar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Terrault</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases.</article-title>
            <source>Hepatology</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>318</fpage>
            <page-range>318-365</page-range>
            <pub-id pub-id-type="pmid">32946672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jhaveri</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kowdley</surname>
                <given-names>KV</given-names>
              </name>
            </person-group>
            <article-title>New developments in the treatment of primary biliary cholangitis - role of obeticholic acid.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2017</year>
            <volume>13</volume>
            <fpage>1053</fpage>
            <page-range>1053-1060</page-range>
            <pub-id pub-id-type="pmid">28860789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiorucci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Giorgio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Distrutti</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2019</year>
            <volume>256</volume>
            <fpage>283</fpage>
            <page-range>283-295</page-range>
            <pub-id pub-id-type="pmid">31201552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Use of Obeticholic Acid in Patients With Primary Biliary Cholangitis.</article-title>
            <source>Gastroenterol Hepatol (N Y)</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>11</issue>
            <fpage>654</fpage>
            <page-range>654-657</page-range>
            <pub-id pub-id-type="pmid">30538606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trauner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nevens</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shiffman</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Drenth</surname>
                <given-names>JPH</given-names>
              </name>
              <name>
                <surname>Bowlus</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Andreone</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hirschfield</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pencek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Malecha</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>MacConell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.</article-title>
            <source>Lancet Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>445</fpage>
            <page-range>445-453</page-range>
            <pub-id pub-id-type="pmid">30922873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gege</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hambruch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hambruch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kinzel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kremoser</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Nonsteroidal FXR Ligands: Current Status and Clinical Applications.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2019</year>
            <volume>256</volume>
            <fpage>167</fpage>
            <page-range>167-205</page-range>
            <pub-id pub-id-type="pmid">31197565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nevens</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Andreone</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mazzella</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Strasser</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Bowlus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Invernizzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Drenth</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Pockros</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Regula</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beuers</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Trauner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Floreani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hohenester</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Luketic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shiffman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Erpecum</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hirschfield</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Marschall</surname>
                <given-names>HU</given-names>
              </name>
              <name>
                <surname>Kowdley</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Hooshmand-Rad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marmon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sheeron</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pencek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>MacConell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pruzanski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>D</given-names>
              </name>
              <collab>POISE Study Group</collab>
            </person-group>
            <article-title>A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Aug</month>
            <day>18</day>
            <volume>375</volume>
            <issue>7</issue>
            <fpage>631</fpage>
            <page-range>631-43</page-range>
            <pub-id pub-id-type="pmid">27532829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pencek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marmon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Liberman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hooshmand-Rad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>9</issue>
            <fpage>936</fpage>
            <page-range>936-40</page-range>
            <pub-id pub-id-type="pmid">27109453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pockros</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Freilich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kohli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lawitz</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hellstern</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Owens-Grillo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Van Biene</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shringarpure</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>MacConell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.</article-title>
            <source>Liver Int</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>11</issue>
            <fpage>2082</fpage>
            <page-range>2082-2093</page-range>
            <pub-id pub-id-type="pmid">31402538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goet</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hirschfield</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Guideline review: British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis treatment and management guidelines.</article-title>
            <source>Frontline Gastroenterol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>316</fpage>
            <page-range>316-319</page-range>
            <pub-id pub-id-type="pmid">31281627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Bowlus</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases.</article-title>
            <source>Hepatology</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>75</volume>
            <issue>4</issue>
            <fpage>1012</fpage>
            <page-range>1012-1013</page-range>
            <pub-id pub-id-type="pmid">34431119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eaton</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Vuppalanchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sathapathy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kamath</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid.</article-title>
            <source>Hepatology</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>1511</fpage>
            <page-range>1511-1514</page-range>
            <pub-id pub-id-type="pmid">31680292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siddiqui</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Van Natta</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Connelly</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vuppalanchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Neuschwander-Tetri</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Tonascia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Loomba</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dasarathy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wattacheril</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chalasani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sanyal</surname>
                <given-names>AJ</given-names>
              </name>
              <collab>NASH CRN</collab>
            </person-group>
            <article-title>Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.</article-title>
            <source>J Hepatol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>72</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-33</page-range>
            <pub-id pub-id-type="pmid">31634532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-124966.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murillo Perez</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hiu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kareithi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adekunle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mayne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Malecha</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ness</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van der Meer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lammers</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Battezzati</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Nevens</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kowdley</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Bruns</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cazzagon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Floreani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Par&#x000e9;s</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Londo&#x000f1;o</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Invernizzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carbone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lleo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Dalekos</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Gatselis</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Thorburn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verhelst</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gulamhusein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>HLA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flack</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mulcahy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Trauner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bowlus</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Lindor</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Corpechot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mells</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hirschfield</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Wason</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>BE</given-names>
              </name>
              <collab>GLOBAL PBC Study Group and the members of the UK-PBC Consortium</collab>
            </person-group>
            <article-title>Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.</article-title>
            <source>Gastroenterology</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>163</volume>
            <issue>6</issue>
            <fpage>1630</fpage>
            <page-range>1630-1642.e3</page-range>
            <pub-id pub-id-type="pmid">36150526</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
